Abstract

Abstract Background The serum metabolome contains potential disease biomarkers, some of which are produced endogenously, derived from the diet, or formed by the gut microbiome. We aimed to characterize metabolomics profiles linked with Crohn Disease (CD), with active CD, and with remitting pre-flare CD. Methods Serum untargeted metabolomics was performed using liquid chromatography Mass Spectrometer (LC/MS). PERMANOVA on beta diversity was used to define factors affecting serum metabolome. Multivariate analyses in MaAsLin2 were applied to identify differentially abundant metabolites between CD and controls, between active CD and those in remission, and between those that subsequently flared and those that remained in remission within 24 months of follow-up. Results The cohort included 202 samples from 53 CD patients and 31 healthy controls (156 samples from CD and 46 from controls; Table 1). 545 metabolites were included in our predefined library and were subsequently analyzed. PERMANOVA on the serum metabolomic data indicated that fasting, age, gender, disease, and subject are significant factors contributing to metabolomics variations. Using multivariate analyses and controlling for fasting, age, gender, and subject, we identified 34 specific metabolites that were significantly higher in CD and 26 that were significantly higher in Controls (FDR<0.25; Fig. 1). CD samples were significantly enriched for purine derivatives, simple sugars, and histidine, compared to healthy controls. In contrast, amino-acids, caffeine, and TCA cycle related metabolites were consistently downregulated in CD. 37 metabolites were higher in active CD and 24 in quiescent CD. Saturated fatty acids and acetylated amino-acids were positively correlated with active CD, while histidine and other standard amino-acids were downregulated in active samples compared to remission. Interestingly, acetylated amino acids, asparagine and phenylalanine, were also significantly correlated with CRP. A sub-cohort of 25 CD subjects was enrolled during remission and monitored every 3 months over 2 years. During that prospective follow-up, 11 flared. Focusing on the pre-flare samples, patients who eventually flared showed a significant reduction in N-acetyl glycine and reduction in two ketogenic derivates, acetoacetate and 3-hydroxybutyric acid, in comparison to patients who remained in remission throughout (FDR<0.15). Conclusion CD, CD activity, and a subsequent flare in CD patients with longitudinal data were associated with distinct serum metabolic signature after controlling for confounders like age, gender, and fasting. Additional validation is needed to test if these can be used as predictive biomarkers.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.